Full Breakdown
UltraSight Secures $24 Million Series B2 Funding to Expand AI-Guided Cardiac Ultrasound
By Drooid · · How we work
Core Event
UltraSight, an Israeli med-tech startup, announced Wednesday that it closed a $24 million Series B2 round led by the Alive HealthTech Growth Fund, with participation from Deep Insight, Star51 Capital, Connecticut Innovations, eHealth Ventures and existing backers Mayo Clinic Ventures, NYU and Iron Nation. The capital will fund expansion into U.S. health-system markets and new workflows for intensive-care and mechanical-circulatory-support settings.
Background & Context
Founded in 2018, UltraSight created the “Echosystem” platform to address a shortage of trained sonographers and cardiologists. The system blends structured training, real-time AI guidance and analytics so clinicians can perform focused cardiac ultrasounds under physician oversight. Demand for cardiac imaging is rising while hospitals face workforce constraints that can delay diagnosis.
Key Figures & Groups
- Davidi Vortman – CEO and Co-Founder
- Rick Geoffrion – Chairman, former cardiovascular-device executive
- Dudi Klein – Co-Founder and Managing Partner, Alive HealthTech Growth Fund
- Mayo Clinic Ventures – Investor with a not-for-profit reinvestment mandate
- Prof. Rafi Beyar – Interventional cardiologist, Alive General Partner
Data & Statistics
- Series B2 amount: $24 million
- Total capital raised: $42 million
- Deployments: >10 commercial sites in intensive-care units
- Clinical validation (JAMA Cardiology, Aug 28 2026) showed 93 % sensitivity and 96 % specificity for AI-guided detection of moderate-or-greater aortic stenosis by novice operators.
- Workforce: 25 employees (19 in Israel, the rest in the U.S.)
Official Statements & Responses
Vortman said the funding will accelerate market adoption and patient access to high-quality cardiac ultrasound. Geoffrion noted UltraSight is tackling a long-standing gap in cardiac-care imaging. Klein highlighted the blend of clinical evidence and a scalable model as a response to specialist shortages. The Mayo Clinic clarified that any revenue will support its not-for-profit mission.
Verbatim Quotes
- “We are entering this next stage as our FDA-cleared portfolio continues to expand to support broader cardiac imaging workflows,” — Davidi Vortman
- “UltraSight combines clinical evidence with a scalable commercial model in a market constrained by access and workforce shortages,” — Dudi Klein
Why It Matters / Impact
By separating image acquisition from specialized sonography while keeping physician-led interpretation, UltraSight aims to cut waiting times, improve patient flow and extend cardiac-imaging capabilities to hospitals lacking round-the-clock sonographer coverage. The expanded FDA-cleared portfolio positions the company to address workforce shortages that have limited timely diagnosis of structural-heart disease.
What’s Next
The new capital will be used to scale commercial operations across U.S. health systems, deepen implementation in intensive-care and circulatory-support environments, and generate further clinical evidence for additional cardiac-care applications. Upcoming board appointments—including Dudi Klein, Tal Wenderow and Barak Ben-Eliezer—will bolster strategic guidance as UltraSight pursues broader adoption of its AI-guided workflow.